Conditions: Coronary Heart Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS). Treatment will be initiated within 1 week after the ACS. Patients will be randomized to receive dalcetrapib 600 mg as daily oral doses or matching placebo. The anticipated time on study treatment is 20 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: dalcetrapib intervention 2: placebo
Intervention descriptions: intervention 1: Oral doses of 600 mg once daily for 20 weeks intervention 2: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks

Protocol document: